Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Cluster Headache Syndrome (Cluster Headache) - Overview
Cluster Headache Syndrome (Cluster Headache) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Cluster Headache Syndrome (Cluster Headache) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cluster Headache Syndrome (Cluster Headache) - Companies Involved in Therapeutics Development
CCH Pharmaceuticals ApS
Clexio Biosciences Ltd
Crossject SA
Eli Lilly and Co
Mind Medicine Inc
NeuroPharm Inc
TrioxBio Inc
Winston Pharmaceuticals Inc
Zosano Pharma Corp
Cluster Headache Syndrome (Cluster Headache) - Drug Profiles
CLE-500 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
galcanezumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ketamine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cluster Headache Syndrome (Cluster Headache) - Dormant Projects
Cluster Headache Syndrome (Cluster Headache) - Discontinued Products
Cluster Headache Syndrome (Cluster Headache) - Product Development Milestones
Featured News & Press Releases
Jun 08, 2020: Phase 2 clinical trial of LSD for "Suicide Headaches" begins treating patients
Feb 27, 2020: CHMP adopted a negative opinion for an extension of indication for Emgality
Jul 11, 2019: New England Jourl of Medicine publishes positive phase 3 data for Emgality (galcanezumab-gnlm) in episodic cluster headache
Jun 05, 2019: FDA approves first drug for episodic cluster headaches
May 02, 2019: Lilly to present new data at AAN 2019 on Emgality (galcanezumab-gnlm) reinforcing breadth of headache disorders portfolio
Mar 05, 2019: Lilly receives FDA Priority Review Desigtion for Emgality (galcanezumab-gnlm) Injection for the preventive treatment of Episodic Cluster Headache in Adults
Nov 14, 2018: Emgality receives Breakthrough Therapy Desigtion for prevention of Episodic Cluster Headache
May 15, 2018: Lilly’s Galcanezumab Meets Primary Endpoint in Phase 3 Study Evaluating Galcanezumab for the Prevention of Episodic Cluster Headache
Sep 06, 2017: Lilly To Present New Data For Galcanezumab At The 18th Congress Of The Intertiol Headache Society
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Cluster Headache Syndrome (Cluster Headache), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020


List of Tables


Number of Products under Development for Cluster Headache Syndrome (Cluster Headache), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Cluster Headache Syndrome (Cluster Headache) - Pipeline by CCH Pharmaceuticals ApS, H2 2020
Cluster Headache Syndrome (Cluster Headache) - Pipeline by Clexio Biosciences Ltd, H2 2020
Cluster Headache Syndrome (Cluster Headache) - Pipeline by Crossject SA, H2 2020
Cluster Headache Syndrome (Cluster Headache) - Pipeline by Eli Lilly and Co, H2 2020
Cluster Headache Syndrome (Cluster Headache) - Pipeline by Mind Medicine Inc, H2 2020
Cluster Headache Syndrome (Cluster Headache) - Pipeline by NeuroPharm Inc, H2 2020
Cluster Headache Syndrome (Cluster Headache) - Pipeline by TrioxBio Inc, H2 2020
Cluster Headache Syndrome (Cluster Headache) - Pipeline by Winston Pharmaceuticals Inc, H2 2020
Cluster Headache Syndrome (Cluster Headache) - Pipeline by Zosano Pharma Corp, H2 2020
Cluster Headache Syndrome (Cluster Headache) - Dormant Projects, H2 2020
Cluster Headache Syndrome (Cluster Headache) - Discontinued Products, H2 2020